GENOMED
Research GENOMED (GEN.WA) on Bullrun: market cap PLN 49.15M, P/E 15.3, dividend yield 3.8%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGEN.WA
- ExchangeXNCO
- CountryPoland
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyPLN
- Market capPLN 49.15M
- P/E15.3
- Dividend yield3.8%
- Financial periodQ1 2026
- RevenuePLN 6.76M
- Net income-PLN 48.57K
- Free cash flow-PLN 574.71K
- Gross margin59.9%
Valuation Snapshot
latest market cap is PLN 49.15M; P/E is 15.3; dividend yield is 3.8%.
Peer valuation comparison
Latest P/E is 15.27x versus a Healthcare sector median of 24.64x (38.0% below).
Latest dividend yield is 3.75% versus a Healthcare sector median of 1.83% (105.5% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | PLN 29.12M | PLN 3.36M | PLN 1.98M | 66.4% | 2.6 | PLN 6.10M | n/a | PLN 14.12M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-10 | PLN 49.15M | 15.3 | 4.0% | 1.5 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1.5 PLN, yield 3.8%.
About GENOMED
Genomed Spólka Akcyjna provides DNA and RNA sequencing and analysis and diagnostics services for congenital diseases in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company's diagnostic services include DNA isolation, PCR amplification of chosen DNA regions, comparison of the sequences, and interpretation of the results by diagnosticians.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is GENOMED's market cap?
GENOMED's market capitalization is PLN 49.15M.
What is GENOMED's P/E ratio?
GENOMED's price-to-earnings (P/E) ratio is 15.3.
Does GENOMED pay a dividend?
GENOMED has a dividend yield of 3.8%.
What does GENOMED do?
Genomed Spólka Akcyjna provides DNA and RNA sequencing and analysis and diagnostics services for congenital diseases in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company's diagnostic services include DNA isolation, PCR amplification of chosen DNA regions, comparison of the sequences, and interpretation of the results by diagnosticians.